KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $111.8 million.

  • West Pharmaceutical Services' Accumulated Expenses rose 4045.23% to $111.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.8 million, marking a year-over-year increase of 4045.23%. This contributed to the annual value of $73.5 million for FY2024, which is 3059.49% down from last year.
  • As of Q3 2025, West Pharmaceutical Services' Accumulated Expenses stood at $111.8 million, which was up 4045.23% from $93.4 million recorded in Q2 2025.
  • West Pharmaceutical Services' Accumulated Expenses' 5-year high stood at $116.3 million during Q4 2021, with a 5-year trough of $65.7 million in Q1 2023.
  • Moreover, its 5-year median value for Accumulated Expenses was $79.6 million (2024), whereas its average is $84.8 million.
  • In the last 5 years, West Pharmaceutical Services' Accumulated Expenses tumbled by 3396.39% in 2022 and then surged by 4045.23% in 2025.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Accumulated Expenses stood at $116.3 million in 2021, then tumbled by 33.96% to $76.8 million in 2022, then skyrocketed by 37.89% to $105.9 million in 2023, then tumbled by 30.59% to $73.5 million in 2024, then skyrocketed by 52.11% to $111.8 million in 2025.
  • Its Accumulated Expenses was $111.8 million in Q3 2025, compared to $93.4 million in Q2 2025 and $67.8 million in Q1 2025.